GlassScriptPrepare for your visit
Waleed Najeeb
Pulmonary Disease · Glendale, WI · NPI 1407879877
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$26,426.29
in general payments reported to CMS, 2019-2025 · $2,501 in 2025
The $2,501 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Who reported paying
General payments only, top 6 by amount.
- Gilead Sciences, INC. $7,614.49
- Astrazeneca Pharmaceuticals LP $3,123.32
- Abbvie INC. $1,776.17
- Boehringer Ingelheim Pharmaceuticals, INC. $1,540.80
- Janssen Pharmaceuticals, INC $1,310.23
- Glaxosmithkline, LLC. $1,159.45
Drugs and devices associated with these payments
Breztri Dupixent Zenpep Kerendia Fasenra Vraylar Linzess Airsupra Jardiance Nucala Xarelto Ofev
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Waleed Najeeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/109412/waleed-najeeb